CN100404041C - 一种治疗冠心病的药物组合物 - Google Patents
一种治疗冠心病的药物组合物 Download PDFInfo
- Publication number
- CN100404041C CN100404041C CNB2004100198273A CN200410019827A CN100404041C CN 100404041 C CN100404041 C CN 100404041C CN B2004100198273 A CNB2004100198273 A CN B2004100198273A CN 200410019827 A CN200410019827 A CN 200410019827A CN 100404041 C CN100404041 C CN 100404041C
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- composition according
- amount
- borneolum syntheticum
- salviae miltiorrhizae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 7
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 81
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 32
- 238000000605 extraction Methods 0.000 claims abstract description 28
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 26
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 26
- 239000000463 material Substances 0.000 claims abstract description 12
- 239000003513 alkali Substances 0.000 claims abstract description 7
- 239000002994 raw material Substances 0.000 claims abstract 2
- 239000000706 filtrate Substances 0.000 claims description 34
- 239000006187 pill Substances 0.000 claims description 31
- 239000000047 product Substances 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
- 239000002671 adjuvant Substances 0.000 claims description 16
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000012567 medical material Substances 0.000 claims description 14
- 229940057995 liquid paraffin Drugs 0.000 claims description 13
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims description 12
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 11
- 239000002244 precipitate Substances 0.000 claims description 10
- 238000004064 recycling Methods 0.000 claims description 10
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 239000002552 dosage form Substances 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 102000011759 adducin Human genes 0.000 claims description 3
- 108010076723 adducin Proteins 0.000 claims description 3
- 238000010411 cooking Methods 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001476 alcoholic effect Effects 0.000 claims 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 3
- 241000411851 herbal medicine Species 0.000 abstract description 2
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 1
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 abstract 1
- 229940116229 borneol Drugs 0.000 abstract 1
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 1
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 1
- 244000132619 red sage Species 0.000 abstract 1
- 238000001914 filtration Methods 0.000 description 21
- -1 nitrous acid ester Chemical class 0.000 description 15
- 238000000034 method Methods 0.000 description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 8
- 244000131316 Panax pseudoginseng Species 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 230000008859 change Effects 0.000 description 8
- 208000010125 myocardial infarction Diseases 0.000 description 8
- 238000010298 pulverizing process Methods 0.000 description 8
- 230000006907 apoptotic process Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 230000006837 decompression Effects 0.000 description 7
- 239000004744 fabric Substances 0.000 description 7
- 239000002932 luster Substances 0.000 description 7
- 239000002304 perfume Substances 0.000 description 7
- 235000013599 spices Nutrition 0.000 description 7
- 239000004698 Polyethylene Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 208000028867 ischemia Diseases 0.000 description 6
- 229920000573 polyethylene Polymers 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000004165 myocardium Anatomy 0.000 description 5
- 210000004413 cardiac myocyte Anatomy 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000002107 myocardial effect Effects 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 238000003908 quality control method Methods 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 241000233855 Orchidaceae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000003680 myocardial damage Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010008469 Chest discomfort Diseases 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001709 ictal effect Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000009191 jumping Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000007962 solid dispersion Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Claims (14)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100198273A CN100404041C (zh) | 2004-06-30 | 2004-06-30 | 一种治疗冠心病的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100198273A CN100404041C (zh) | 2004-06-30 | 2004-06-30 | 一种治疗冠心病的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1714819A CN1714819A (zh) | 2006-01-04 |
CN100404041C true CN100404041C (zh) | 2008-07-23 |
Family
ID=35821179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100198273A Active CN100404041C (zh) | 2004-06-30 | 2004-06-30 | 一种治疗冠心病的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100404041C (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102028743B (zh) * | 2009-09-29 | 2014-12-24 | 天津天士力现代中药资源有限公司 | 一种治疗冠心病的药物及制备 |
CN102028740A (zh) * | 2009-09-29 | 2011-04-27 | 天津天士力现代中药资源有限公司 | 一种治疗冠心病的药物及其制备工艺 |
CN102028746B (zh) * | 2009-09-29 | 2014-12-24 | 天津天士力现代中药资源有限公司 | 一种治疗冠心病的药物及提取 |
CA2807283C (en) * | 2010-08-06 | 2019-05-14 | Xijun Yan | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease |
HUE054609T2 (hu) | 2013-07-11 | 2021-09-28 | Tasly Pharmaceutical Group Co | Elkészítési eljárás hagyományos kínai gyógyszer mikrocsepp pilulához, és a hagyományos kínai gyógyszer mikrocsepp pilula, amely ennek az eljárásnak az alkalmazásával van elkészítve |
EP3020408B1 (en) * | 2013-07-11 | 2022-01-12 | Tasly Pharmaceutical Group Co., Ltd. | Traditional chinese medicine composition, and preparation and application thereof |
USRE49050E1 (en) | 2013-07-11 | 2022-04-26 | Tasly Pharmaceutical Group Co., Ltd. | Traditional Chinese medicine composition, and preparation and application thereof |
CN104418744B (zh) | 2013-08-29 | 2017-03-01 | 天士力制药集团股份有限公司 | 一种新的丹酚酸化合物t、其制备方法和用途 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1249943A (zh) * | 1999-08-11 | 2000-04-12 | 河北省药品检验所 | 复方丹参片制取新工艺 |
-
2004
- 2004-06-30 CN CNB2004100198273A patent/CN100404041C/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1249943A (zh) * | 1999-08-11 | 2000-04-12 | 河北省药品检验所 | 复方丹参片制取新工艺 |
Non-Patent Citations (2)
Title |
---|
丹七制剂提取工艺的优化实验研究. 袁媛,韦晓晖,杨俊毅,等.华西药学杂志,第17卷第1期. 2002 |
丹七制剂提取工艺的优化实验研究. 袁媛,韦晓晖,杨俊毅,等.华西药学杂志,第17卷第1期. 2002 * |
Also Published As
Publication number | Publication date |
---|---|
CN1714819A (zh) | 2006-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825791B (zh) | 一种具有抗疲劳功能的中药保健品及其制备方法 | |
CN100404041C (zh) | 一种治疗冠心病的药物组合物 | |
CN102475830B (zh) | 一种治疗冠心病心绞痛的药物组合物与其制备方法及制剂 | |
CN103610659A (zh) | 一种大蒜素药物组合物及其制备方法 | |
CN102240385A (zh) | 用于治疗妇女产后疾病的中药滴丸及其制备方法 | |
CN108498576A (zh) | 一种治疗心脑血管疾病的药物及其制备方法 | |
CN101278958A (zh) | 肺宁滴丸及其制备方法 | |
CN101011562A (zh) | 参芪温胆汤新剂型及其生产方法 | |
CN101172155A (zh) | 生脉温胆汤新剂型及其生产方法 | |
CN101700275A (zh) | 一种含广枣的药物制剂及其制备方法与应用 | |
CN102697910B (zh) | 一种治疗糖尿病和高血脂的中药提取物滴丸 | |
CN103191308A (zh) | 一种复方霍斛蓉芝含片及其生产工艺 | |
CN1872232B (zh) | 治疗脑血管疾病的药物组合物及其制备方法 | |
CN100367938C (zh) | 四黄泻火滴丸及其制备方法 | |
CN100563635C (zh) | 一种藿香正气滴丸 | |
CN101856357B (zh) | 救必应酸在制备防治心脑血管疾病的药物中的应用 | |
CN1872230B (zh) | 一种治疗冠心病心绞痛的药物及其制备方法 | |
US7179492B2 (en) | Traditional chinese pharmaceutical formulation for treatment of paradentosis&comma; process for preparation and use thereof | |
CN101919919A (zh) | 腹可安分散片及其制备方法 | |
CN101766683B (zh) | 一种丹参分散片及其应用 | |
CN1872250B (zh) | 一种治疗头痛的药物组合物 | |
CN100563634C (zh) | 一种小柴胡汤滴丸 | |
CN101491628A (zh) | 一种杞菊地黄制剂及其制备方法 | |
CN100421684C (zh) | 一种治疗冠心病心绞痛的药物 | |
CN100358562C (zh) | 川贝枇杷滴丸及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C56 | Change in the name or address of the patentee |
Owner name: TASLY PHARMACEUTICAL GROUP CO., LTD. Free format text: FORMER NAME: TIANJIN TASLY PHARMACEUTICAL CO., LTD. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Co., Ltd. Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tianjin Tianshili Pharmaceutical Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |
Address after: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee after: Tasly Pharmaceutical Group Limited by Share Ltd Address before: 300402, No. 1, Liaohe East Road, Beichen Science Park, Beichen District, Tianjin Patentee before: Tasly Pharmaceutical Group Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |